Kala Pharmaceuticals Inc (NASDAQ:KALA) Receives $20.67 Consensus Target Price from Analysts

Kala Pharmaceuticals Inc (NASDAQ:KALA) has been assigned a consensus rating of “Buy” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $20.67.

Several analysts have weighed in on KALA shares. Wedbush reiterated an “outperform” rating and issued a $51.00 price objective on shares of Kala Pharmaceuticals in a research note on Wednesday, August 7th. ValuEngine upgraded shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Oppenheimer set a $9.00 price objective on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 7th. HC Wainwright dropped their price objective on shares of Kala Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, August 7th. Finally, Zacks Investment Research cut shares of Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 14th.

Kala Pharmaceuticals stock remained flat at $$4.55 during midday trading on Tuesday. 253,407 shares of the company’s stock traded hands, compared to its average volume of 262,838. Kala Pharmaceuticals has a twelve month low of $3.50 and a twelve month high of $11.09. The company has a debt-to-equity ratio of 1.16, a quick ratio of 7.04 and a current ratio of 7.50. The company has a fifty day simple moving average of $4.35 and a 200-day simple moving average of $6.18. The company has a market capitalization of $154.73 million, a P/E ratio of -1.83 and a beta of 2.15.



Kala Pharmaceuticals (NASDAQ:KALA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.04. The business had revenue of $2.06 million during the quarter, compared to analyst estimates of $2.62 million. As a group, equities research analysts forecast that Kala Pharmaceuticals will post -2.75 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of KALA. BlackRock Inc. raised its position in shares of Kala Pharmaceuticals by 20.3% in the 2nd quarter. BlackRock Inc. now owns 1,684,802 shares of the company’s stock valued at $10,749,000 after buying an additional 283,747 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Kala Pharmaceuticals by 25.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,237,683 shares of the company’s stock valued at $7,896,000 after buying an additional 248,287 shares in the last quarter. Boston Partners raised its position in shares of Kala Pharmaceuticals by 542.6% in the 2nd quarter. Boston Partners now owns 118,431 shares of the company’s stock valued at $756,000 after buying an additional 100,000 shares in the last quarter. Alambic Investment Management L.P. raised its position in shares of Kala Pharmaceuticals by 108.0% in the 2nd quarter. Alambic Investment Management L.P. now owns 86,487 shares of the company’s stock valued at $552,000 after buying an additional 44,899 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Kala Pharmaceuticals in the 1st quarter valued at approximately $325,000. Institutional investors own 68.63% of the company’s stock.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Article: Forex

Analyst Recommendations for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.